Endoscopy Practice and Sedation

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 28.1: Pre-procedure fasting and pregnancy testing

  Pre-procedure fasting reduces the gastric volume and acidity that drive aspiration risk during sedation.

• Section 28.2: Procedure bleeding risk and thromboembolism risk stratification

  Periprocedural antithrombotic management starts with two questions: what is the bleeding risk of the planned procedure, and what is the thromboembolic risk of the patient.

• Section 28.3: Warfarin and DOAC periprocedural management

  Warfarin and direct oral anticoagulants share the same goal (anticoagulation through factor inhibition) but differ in pharmacokinetics, reversibility, and procedural hold strategy.

• Section 28.4: Bridging and the BRIDGE/PERIOP-2 evidence

  Bridging with low-molecular-weight heparin during warfarin interruption was once standard practice but has been narrowed dramatically since 2015 based on randomized trial data.

• Section 28.5: Antiplatelet management and DAPT after coronary stenting

  Antiplatelet management in endoscopy turns on a single principle: the risk math is asymmetric.

• Section 28.6: Antithrombotic reversal in active bleeding

  When active bleeding requires antithrombotic reversal, the choice of agent depends on the drug being reversed and the urgency.

• Section 28.7: Sedation depth, ASA, and pharmacology

  Sedation choices for endoscopy span minimal sedation (anxiolysis), moderate (conscious) sedation, deep sedation, and general anesthesia.

• Section 28.8: Capnography, difficult airway, and reversal

  Sedation safety depends on three layers: real-time monitoring of ventilation, anticipation of the difficult airway, and prompt reversal when respiratory or sedation depression overshoots the intended target.

• Section 28.9: Sedation in special populations

  Standard sedation regimens require modification in specific populations because pharmacokinetics or aspiration risk changes the calculation.

• Section 28.10: Antibiotic prophylaxis

  Antibiotic prophylaxis is recommended for a narrow set of endoscopic scenarios and is explicitly not recommended for many situations where it is reflexively given.

• Section 28.11: GLP-1 and SGLT-2 inhibitors

  The 2024 to 2025 multi-society guidance addressed two newer drug classes that affect endoscopy and were not part of earlier curricula: glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors.

• Section 28.12: Pacemakers, ICDs, and electromagnetic interference

  Cardiac implantable electronic devices (CIEDs) interact with endoscopic electrosurgery through electromagnetic interference.

• Section 28.13: Capsule endoscopy

  Capsule endoscopy uses a swallowed wireless camera that traverses the gastrointestinal tract and transmits images to an external recorder, providing visualization of the small bowel that conventional endoscopy cannot reach.

• Section 28.14: ASGE adverse event lexicon

  The ASGE adverse event lexicon (Cotton 2010, Gastrointestinal Endoscopy) provides a standardized framework for recognizing and grading endoscopic adverse events across procedures and institutions.

Podcast episodes

1. 01

   Fasting and Periprocedural Antithrombotics

   Episode one of the Endoscopy Practice and Sedation chapter frames the morning of the procedure around two preventable disasters: aspiration and thromboembolism. The organizing idea is that fasting intervals are gastric-emptying kinetics on a clock, and every anticoagulant decision sits at the intersection of procedure bleeding risk and patient thromboembolic risk. That grid tells you who holds, who continues, and who bridges. A single asymmetry runs the antiplatelet decisions: an unrecognized stent thrombosis dwarfs endoscopically manageable bleeding, which is why aspirin usually stays on. Reversal closes the loop, each agent matched to its target.

   Read the transcript →
2. 02

   Sedation Depth and Agents

   Episode two frames procedural sedation around one trade: the depth you want versus the depth your team can rescue from. The ASA continuum sets the rescue rule, the practitioner must be able to manage a patient one level deeper than intended, and ASA physical status predicts who tolerates endoscopist-supervised moderate sedation versus who needs anesthesia. Midazolam and fentanyl carry the easy case at the cost of multiplicative respiratory depression; propofol buys fast onset and offset for the complex case at the cost of no antagonist. The alternative agents each solve one problem the standard pair cannot.

   Read the transcript →
3. 03

   Sedation Monitoring and Special Populations

   Episode three covers the monitoring, prediction, and rescue that catch the patient when the drug carries them past the intended depth. Capnography detects apnea within one to two breaths while pulse oximetry lags on supplemental oxygen, so a flat waveform with a reassuring saturation is apnea. Mallampati and the airway predictors decide whether the standard plan is safe before the first dose, and flumazenil and naloxone reverse the agents but wear off faster than what they reverse. The special populations are not exceptions, they are the same framework run through a shifted pharmacokinetic and aspiration-risk profile.

   Read the transcript →
4. 04

   Antibiotics, Devices, Capsule, and Adverse Events

   Episode four closes the chapter on four topics that each test one recognition: when the reflexive answer is wrong because the underlying principle has shifted. Antibiotic prophylaxis turns on closed-space infection, not the prosthetic device, so the 2007 AHA guideline took GI endoscopy off the endocarditis list. Cardiac device management turns on electromagnetic interference, so modern pacemakers tolerate routine polypectomy without reprogramming while ICDs need arrhythmia detection suspended. Capsule endoscopy lives or dies on retention risk addressed by the patency capsule, and the ASGE Cotton lexicon grades adverse events by intensity of intervention.

   Read the transcript →

Key topics

• ·Fasting intervals and delayed-emptying exceptions
• ·GLP-1 receptor agonists and aspiration risk
• ·Procedure bleeding risk versus patient thromboembolic risk
• ·Warfarin holds and morning-of INR
• ·DOAC holds scaled to half-life and kidney function
• ·The narrowing of bridging
• ·Antiplatelet management after coronary stenting
• ·Reversal agents in active bleeding
• ·The intended-versus-rescuable depth trade
• ·ASA sedation continuum and the rescue rule
• ·ASA physical status classification
• ·Midazolam plus fentanyl pharmacology and dosing
• ·Multiplicative benzodiazepine-opioid respiratory depression
• ·Propofol kinetics and staffing implications
• ·Etomidate, ketamine, and dexmedetomidine
• ·Capnography versus pulse oximetry lag
• ·Mallampati and difficult-airway predictors
• ·Aspiration risk and rapid sequence induction
• ·Flumazenil and naloxone reversal
• ·Cirrhosis and altered sedative handling
• ·Elderly dose reduction
• ·Obstructive sleep apnea and STOP-BANG
• ·Pregnancy agent selection
• ·Updated GLP-1 periprocedural guidance
• ·Endocarditis prophylaxis off the GI list
• ·The closed-space infection principle
• ·Incomplete ERCP drainage and cyst FNA prophylaxis
• ·Pacemakers and monopolar electrosurgery
• ·ICDs and arrhythmia detection
• ·Capsule endoscopy retention